There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy
(warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in
nonvalvular atrial fibrillation (NVAF) requires continued evaluation.